Stockscreener 앱 받기
106.85
5.46%
5.53
시간 외 거래:
107.00
0.15
+0.14%
전일 마감가:
$101.32
열려 있는:
$105.84
하루 거래량:
228.81K
Relative Volume:
0.59
시가총액:
$1.57B
수익:
$1.30M
순이익/손실:
$-140.06M
주가수익비율:
-11.81
EPS:
-9.0441
순현금흐름:
$-129.83M
1주 성능:
-2.43%
1개월 성능:
-17.21%
6개월 성능:
+27.72%
1년 성능:
+730.87%
1일 변동 폭
$99.20
$108.75
1주일 범위
$99.00
$113.95
52주 변동 폭
$12.68
$155.29
인히브릭스 Stock (INBX) Company Profile
명칭
Inhibrx Biosciences Inc
전화
(858) 795-4220
주소
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
106.85 | 1.49B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
인히브릭스 Stock (INBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 개시 | Stifel | Buy |
| 2024-07-23 | 개시 | JMP Securities | Mkt Perform |
| 2024-01-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 개시 | SMBC Nikko | Outperform |
| 2021-09-21 | 개시 | JMP Securities | Mkt Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Evercore ISI | Outperform |
모두보기
인히브릭스 주식(INBX)의 최신 뉴스
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00 - MSN
Inhibrx Inc stock (US45720L1070): trial update around ozekibart keeps biotech investors watching - AD HOC NEWS
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation - AASTOCKS.com
創勝集團(06628.HK)：ozekibart中期研究數據積極 評估大中華區計劃 - AASTOCKS.com
Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study - MSN
Inhibrx Biosciences, Inc.Common Stock (NQ: INBX - The Chronicle-Journal
This biotech stock surges after positive cancer trial results. What to know. - MSN
Liquidity Mapping Around (INBX) Price Events - Stock Traders Daily
Inhibrx cancer treatment shows high response rates in head and neck cancer study - MSN
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Viking Global holds 1.46M shares in Inhibrx (INBX); amendment removes one reporter - Stock Titan
Perceptive (INBX) reports a 9.99% stake in INHIBRx via Schedule 13G/A - Stock Titan
Inhibrx Biosciences 1Q Loss/Shr $2.15 >INBX - Moomoo
Inhibrx Reports First Quarter 2026 Financial Results - Arizona Daily Sun
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325 - Moomoo
Inhibrx & Invesco Mortgage Capital Q1 2026 Results - Punjab Kesari English
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer - BioPharma APAC
Inhibrx Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibrx Biosciences (INBX) cuts Q1 2026 loss, boosts cash but ups debt - Stock Titan
Inhibrx Biosciences (INBX) advances ozekibart BLA and INBRX-106 after strong oncology data - Stock Titan
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study - Insider Monkey
Inhibrx Inc stock (US45720L1070): Biotech firm in Virtus ETF holdings - AD HOC NEWS
Inhibrx seeks FDA OK for cancer drug as Q1 loss totals $33.4M - Stock Titan
INBX Stock Price, Quote & Chart | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors? - Yahoo Finance
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study - Sahm
Inhibrx Biosciences (INBX) Stock Jumps 17% on Positive Cancer Trial Results - MEXC Exchange
Inhibrx Biosciences (INBX) Stock Soars 17% Following Impressive Phase 2 Cancer Data - MEXC Exchange
This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know. -- Barrons.com - Moomoo
Inhibrx Biosciences Reports Positive Interim Phase 2 Results - TipRanks
INBRX106 trial update signals pipeline progress at Inhibrx Biosciences - Traders Union
INBRX-106 boosts response in HNSCC for Inhibrx (Nasdaq: INBX) with Phase 2 results - Stock Titan
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap UpHere's What Happened - MarketBeat
Why Is Inhibrx Biosciences Stock Trading Higher Today?Inhibrx Biosciences (NASDAQ:INBX) - Benzinga
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Inhibrx reports interim phase 2 data for cancer drug trial - Investing.com UK
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study - Barchart.com
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know. - Barron's
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know. -- Barrons.com - Moomoo
TradingKey - TradingKey
Inhibrx Biosciences (INBX) Shares Surge 17% Following Promising Head and Neck Cancer Data - parameter.io
Inhibrx Biosciences (INBX) Shares Soar 17% Following Promising Phase 2 Cancer Study Data - MoneyCheck
Inhibrx Biosciences reports positive Ph2 trial data, stock gains By Investing.com - Investing.com Nigeria
Inhibrx Biosciences reports positive Ph2 trial data, stock gains - Investing.com India
인히브릭스 (INBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):